Ownership and insider activity for Nautilus Biotechnolgy, Inc. (NAUT): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.
Price
| Price | $0.97 |
| Market Cap | $124M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-18 | Posard Matthew L. | A-Award | 45,000 | $103K |
| 2026-06-18 | NAZEM FARZAD | A-Award | 45,000 | $103K |
| 2026-06-18 | Akinsanya Karen | A-Award | 45,000 | $103K |
| 2026-06-18 | McIlwain Matthew S | A-Award | 45,000 | $103K |
| 2026-06-18 | Epperly Melissa B, | A-Award | 45,000 | $103K |
| 2026-06-02 | AH Equity Partners Bio II, L.L.C. | S-Sale | 4,615,974 | $10.8M |
| 2026-06-02 | AH Equity Partners Bio II, L.L.C. | S-Sale | 384,026 | $902K |
| 2026-03-04 | Patel Sujal M | P-Purchase | 25,000 | $65K |
| 2026-03-02 | Mowry Anna | A-Award | 160,000 | $371K |
| 2026-03-02 | Mallick Parag | A-Award | 280,000 | $650K |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.2M | $595000 | $36.6M | $185.6M | $114.5M | $19.4M | $27.6M | $12.4M |
| Short-term Investments | $144.49B | $16.1M | $40.1M | $160.1M | $69.9M | $154.0M | $102.2M | $91.0M |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $1.3M | $17.0M | $77.7M | $349.2M | $187.2M | $176.8M | $132.8M | $106.0M |
| Property, Plant & Equipment | 0 | $1.1M | $6.2M | $31.9M | $32.6M | $36.9M | $32.3M | $31.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $145.8M | $18.5M | $85.0M | $398.4M | $350.1M | $305.6M | $242.7M | $191.1M |
| Accounts Payable | 0 | $289000 | $470000 | $1.7M | $1.3M | $1.6M | $987000 | $943000 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $5000 | $490000 | $3.0M | $5.8M | $6.8M | $9.1M | $7.6M | $8.0M |
| Long-term Debt | $5.0M | $275.0M | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $140.8M | $490000 | $114.7M | $34.9M | $35.1M | $40.2M | $34.0M | $34.1M |
| Retained Earnings | $626600 | -$14.7M | -$30.3M | -$80.6M | -$138.6M | -$202.2M | -$273.0M | -$332.0M |
| Total Equity | $5.0M | $18.1M | -$29.7M | $363.6M | $314.9M | $265.4M | $208.7M | $157.0M |
| Total Debt | $5.0M | $275.0M | $4.8M | $30.0M | $30.3M | $34.6M | $30.5M | $30.0M |
| Net Debt | -$144.48B | $258.3M | -$72.0M | -$315.7M | -$154.1M | -$138.8M | -$99.4M | -$73.4M |
| Working Capital | $1.3M | $16.5M | $74.6M | $343.4M | $180.4M | $167.7M | $125.2M | $98.0M |
Financial Health
| Debt / Equity | 0.21 |
| Current Ratio | 10.14 |
Profitability
| Return on Equity | -37.58% |
| Return on Invested Capital | -39.50% |
| Return on Assets | -34.55% |
| Gross Margin | -919.47% |
| Operating Margin | -33043.68% |
| Net Margin | -29747.89% |
Related companies: ARCT · ASMB · ENTA · FHTX · HUMA · IMRX · PYXS
Explore sector: Healthcare · Biotechnology
More sections of NAUT: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks